iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.49% for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2024-11-07
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.93%, a 2.08% increase year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-03-31 was 3.85%.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2021-03-31 was 0.47%.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2021 was 0.47%, a 56.67% increase from fiscal 2020.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2020 was 0.30%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | 3.49% 10-Q · filed 2024-11-07 | ||||||
| 2024-06-30 | 3.93% 10-Q · filed 2024-08-06 | ||||||
| 2024-03-31 | 3.93% 10-Q · filed 2024-05-07 | ||||||
| 2023-09-30 | 3.75% 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 3.75% 10-Q · filed 2024-08-06 | 0.37% 10-Q · filed 2023-08-02 | |||||
| 2023-03-31 | 3.85% 10-Q · filed 2024-05-07 | 0.38% 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | 0.47% 10-K · filed 2022-03-22 | ||||||
| 2021-09-30 | 0.90% 10-Q · filed 2022-11-08 | 0.47% 10-Q · filed 2021-11-04 | |||||
| 2021-06-30 | 0.47% 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 0.47% 10-Q · filed 2022-05-10 | ||||||
| 2020-12-31 | 0.30% 10-K · filed 2022-03-22 | ||||||
| 2020-09-30 | 1.35% 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | 1.35% 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |